We confirmed areas analyzed for LgR5 expression of BE by means of this website immunohistochemical co-labelling with Cdx-2 (Figure 2d). Staining was observed in putative stem cell niches at the bottom of BE and EACs (Figure AZD8931 order 2e). LgR5 Gene Expression Analysis on mRNA Level To confirm the results of the immunohistochemical staining, gene expression of LgR5 in human

EAC was assessed on mRNA level by means of semiquantitative RT-PCR. EAC associated BE (Median 3.5-fold difference compared to normal tissue; IQR 3.025 – 3.725-fold difference; n = 7) exhibited LgR5 gene expression which was significantly (p = 0.0159) higher in comparison to EAC without BE (Median 1.4-fold difference compared to normal tissue; IQR 0.900 – 1.650-fold difference; n = 8; Figure 2f). These results confirmed increased

LgR5 expression in BE adjacent to EAC and significantly decreased expression of LgR5 in EAC without BE as observed by immunohistochemistry. LgR5 RT-PCR results of the OE-33 adenocarinoma cell line showed 4.8-fold difference compared to normal tissue. LgR5 Expression in Relation to Proliferative Activity (Ki-67+) For further investigation of the adoptive role of LgR5 in BE and its relation to potentially cancer-initiating cells in early BE, we analyzed proliferation status of LgR5 expressing early Barrett cells. A small subset of LgR5+ cells were Ki 67+ (proportion of Ki-67 positivity in counted LgR5+ cells was <5%). As shown in Figure 3a and 3b, Ki-67 was co-expressed with only a small subset of LgR5+ cells in areas which were associated with early BE (Cdx-2 positivity was observed in serial Dinaciclib cell line sections) (Figure 3a, representative example of n = 41 BE and associated adenocarcinomas) and OE-33 cells (Figure 3b). Vice versa, most of LgR5+ Barrett cells did not proliferate, as they did not exhibit nuclear staining with the proliferation marker (Ki-67-). In contrast, we analyzed a dominant population of proliferating Ki-67+/LgR5-

cells (Figure 3a). Although down-regulated in EAC with BE, as well as EAC without BE, we confirmed PLEKHB2 a minority of proliferating cells in Cdx-2 negative (Cdx-2-) areas (data not shown). Figure 3 Co-expression of LgR5 with Ki-67 in BE and OE-33 cells by immunofluorescence double staining. Images demonstrate a representative example of LgR5 co-expression with Ki-67 in early BE showing positivity for a small subset of LgR5+ cells with Ki-67+ (arrows). In contrast, a dominant population of proliferating (Ki-67+) Barrett cells were LgR5-, which may drive multi-step carcinogenesis (asterisks). Vice versa, most of LgR5+ Barrett cells were Ki-67- (asterisks). Proliferating LgR5+ OE-33 cells (arrows) are shown below (b). FITC green Fluoresceinisothiocyanat, Cy3 red, and DAPI 4′,6-Diamidino-2- phenylindoldihydrochlorid blue. Top (a), Calibration bar represents 50 μm. Bottom, Calibration bar represents 25 μm (a and b). Case demonstrates area of magnification.